Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: A retrospective, observational study.

Compared with the per-label adequate-dose group, the off-label reduced-dose group had a higher risk of the primary effectiveness outcome of stroke/TIA or SE (per-label adequate-dose vs off-label reduced-dose: 3.05% vs 4.23%; HR: 1.45, 95% CI: 0.80–2.61; adjusted HR: 1.29, [after adjusting for age, diabetes mellitus, and CHA 2 DS 2 -VASc score], 95% CI: 0.71–2.34), the difference of the primary effectiveness endpoint did not reach statistical significance though (Table 2 and Fig. 1 ).

also in 111,027 other papers